Copper depletion boosts CNS leukemia therapy by inhibiting nucleotide synthesis through impairment of mitochondrial complex IV activity.
Blocking copper in leukemia cells starves them of building blocks and enhances chemotherapy, revealing a new strategy for CNS leukemias with stubborn relapse rates.
This Nature Cancer study uncovers that copper depletion impairs mitochondrial complex IV activity to block nucleotide synthesis, enhancing CNS leukemia treatment efficacy. The mechanistic insight identifies copper chelation as a potential adjunct therapeutic strategy for CNS ALL — an area with persistent high relapse rates.
What the study was
- Study design
- Preclinical mechanistic study
- Population
- CNS leukemia models (preclinical, with human translational context)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Nature Cancer
Why it surfaced
Novel mechanism in high-unmet-need CNS leukemia from Nature Cancer; scored conservatively at 5 per non-human study cap — warrants full-text review in Phase 2 to assess human translational content.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.